Camurus ABCAMRF -3.57%79 Current Ratio is 11.57 as of Mar. 2026, which is 204% above its 10-year median of 3.80. GuruFocus rates CAMRF with a GF Score™ of 79/100 and a GF Value™ of $83.14 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 1,417 Biotechnology companies, Camurus AB ranks better than 81.37% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Camurus AB's current ratio for the quarter that ended in Mar. 2026 was 11.57.
Camurus AB has a current ratio of 11.57. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Camurus AB's Current Ratio or its related term are showing as below:
CAMRF'
s Current Ratio Range Over the Past 10 Years
Min: 1.48 Med: 3.8 Max: 12.09
Current: 11.57
During the past 13 years, Camurus AB's highest Current Ratio was 12.09. The lowest was 1.48. And the median was 3.80.
CAMRF's Current Ratio is ranked better than 81.37% of 1417
companies
in the Biotechnology industry
Industry Median: 3.89
vs CAMRF: 11.57
Camurus AB (OTCPK:CAMRF) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Camurus AB Current Ratio Related Terms
Camurus AB Current Ratio Historical Data
* Premium members only.
The historical data trend for Camurus AB's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CAMRF vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Camurus AB's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Camurus AB Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Camurus AB's Current Ratio distribution charts can be found below:
* The bar in red indicates where Camurus AB's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Camurus AB (CAMRF) has a Current Ratio of 11.57 as of Mar. 2026. This is 204% above median its historical median of 3.80. Over the past decade, Camurus AB's Current Ratio has ranged from 1.48 to 12.09. According to the industry distribution chart, Camurus AB ranks #264 out of 1417 companies in the Biotechnology industry, placing it in the top 18.6%.
Is Camurus AB's Current Ratio too high?
Camurus AB's current Current Ratio of 11.57 is 204% above median its 10-year median of 3.80. Over the past 10 years, this metric has ranged from a low of 1.48 to a high of 12.09. The Biotechnology industry median Current Ratio is 3.89. Camurus AB's value of 11.57 is 197.4% above this industry median. Based on the distribution chart, Camurus AB ranks #264 out of 1417 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Camurus AB has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Camurus AB's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Camurus AB ranks #264 out of 1417 companies for Current Ratio. This places Camurus AB in the top 19% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.89. Camurus AB's value of 11.57 is 197.4% above this benchmark. Historically, Camurus AB's own Current Ratio has ranged from 1.48 to 12.09 over the past decade. While the company's 10-year median is 3.80 vs. the industry median of 3.89, Camurus AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Camurus AB's current Current Ratio of 11.57 is 197.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Camurus AB's current Current Ratio is 11.57, which is 204% above median its own 10-year median of 3.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Camurus AB stock overvalued right now?
Based on GuruFocus' analysis, Camurus AB (CAMRF) is currently considered Significantly Undervalued. The stock's GF Value™ is $83.14, compared to a current price of $54.00 — trading 35% below its estimated fair value. The current Current Ratio is 11.57, which is 204% above median its 10-year median of 3.80 and 197.4% above the Biotechnology industry median of 3.89. Camurus AB's overall GF Score™ is 79/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Camurus AB (CAMRF), the current Current Ratio is 11.57 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Camurus AB (CAMRF) Overvalued in 2026?
Based on GuruFocus' analysis, Camurus AB stock appears to be undervalued.
The current stock price of $54.00 is trading 35% below its estimated GF Value™ of $83.14.
GuruFocus considers Camurus AB to be Significantly Undervalued.
Key valuation signals for CAMRF:
Current Ratio: 11.57 (204% above median its 10-year median of 3.80)
GF Value™: $83.14 vs. price of $54.00 (35% below fair value)
Industry Position: 197.4% above the Biotechnology median (#264 of 1417)
No single metric tells the full story. See the CAMRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
79GF Score
Get the complete analysis for CAMRF
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAMRF has been successfully added to your 
